Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Q1

<< Previous

Bullboard Posts

Next >>

Comment by stockfyon Jun 09, 2021 2:10am

156 Views

Post# 33353420

RE:RE:RE:Q1

Well said.

Where are now those cluless posters of this board who blindly followed a clueless analyst Justin Keywood from Stifel and his highly inaccurate forecasts?

Where are now the clueless posters who blindly used Keywood's highly inaccurate projections as BIBLE and dumped CPH at $0.90 and $0.80 a few months ago?

Northforce13 wrote:

After scratching my head a bit, another positive is that I expected earnings to start declining this quarter, and subsequent ones, until something comes along down the road. Yet earnings were much stronger than expected, excluding the legal costs.

The big share price jump appears to have been the result of someone with RBC as a broker sucking up shares aggressively at 1.40+ as of 3:00 PM and on into close. Intriguing -)

Pretty quiet boards